Dow Jones
39.865,16 +307,05 (+0,78%) Nasdaq
16.736,77 +225,59 (+1,37%) Nikkei 225
38.385,73 +29,67 (+0,08%) EUR/USD
1,0883 +0,0061 (+0,57%) Bitcoin EUR
60.661,30 +4.103,12 (+7,25%) CMC Crypto 200
1.388,32 +120,38 (+9,51%)
VERV May 2024 17.500 call
| Chiusura precedente | 0,0200 |
| Aperto | 0,0200 |
| Denaro | 0,0000 |
| Lettera | 0,7500 |
| Prezzo d'esercizio | 17,50 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 0,0200 - 0,0200 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 122 |
GlobeNewswireVerve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
Company to hold investor event in conjunction with data presentation on November 12, 2023BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that the company will present interim data from its ongoing heart-1 Phase 1b clinical trial of VERVE-101 for patients with high-risk heterozygous familial hypercholesterolemia (HeFH) in
- GlobeNewswire
Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference on Thursday, September 28, 2023 at 10:55 a.m. ET in New York. A live webcast will be available in the investor section of
- GlobeNewswire
Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick “Fred” T. Fiedorek, M.D., as chief medical officer (CMO). Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO. “We are excited by the continued expansion of the Verve team and the
